A new Phase 2b clinical trial will confirm the neuroprotective effect of the ApTOLL drug in patients with acute ischemic stroke. The study, with the participation of Vall d'Hebron, has been funded by Ministerio de Ciencia, Innovación y Universidades. More: vhc.cat/nextoll-trial

🧪 #OLIGOFASTX has the leading experts in each field in the area of oligonucleotide research who can provide solutions in the research of new therapies against rare diseases. 🧬 📌 oligofastx.com #fundedbyCDTI

aptaTargets, that has obtained the Seal of Excellence 🏅 from the #EICAccelerator, has been selected by the Comunidad de Madrid to receive a direct grant of €1.940M: bit.ly/3UJI4N0 #ApTOLL #neuroprotection #AcuteIschemicStroke #EUeic #HorizonEurope #NextGenerationEU

Proximo miercoles en el Universidad CEU San Pablo hablaré sobre los #aptameros y sus aplicaciones. Desde aptaTargets trabajamos en el consorcio OLIGOFASTX en el tratamiento de #EnfermedadesRaras como el Síndrome de Guillain-Barré

El próximo miércoles 6 de marzo recibiremos a Miguel Moreno Molina, de aptaTargets, en nuestros seminarios de la Universidad CEU San Pablo . Conoceremos los últimos avances en tecnología de aptámeros. Bienvenido!

We are thrilled to announce that over 1,000 companies in Europe, aptaTargets was selected for the #EICAccelerator by European Innovation Council. It secures €2.5M grant to start the Phase 2b clinical trial with #ApTOLL in patients with #AcuteIschemicStroke: bit.ly/3v5tg0O

Our CSO Macarena Hernández (Macarena Hernández Jiménez) will speak at the 10th European #Stroke Conference next May 15 in Basel. Join us to discover “Tackling the Inflammation: The #APRIL group”. 🕓 3:50 pm 📍 Basel - Room Boston ℹ️ bit.ly/44tCnpm #ESOC2024 #ApTOLL #cytoprotection

There's still time to register for #ESOC2024 in Basel, starting in just a week! 📅 ow.ly/7im650RuF4V Get ready to hear from leading experts, engage in innovative discussions, and be part of the latest advancements in stroke research. #stroke #voiceofstroke #stroketwitter

Today our Clinical Operations Manager Marco Pugliese will speak at "Creative strategies to accelerate patient recruitment rate during study planning" in Barcelona. With Alicia Rami Fortrea, Estrella Garcia (Almirall), Núria Bordas Ferrer and Joseph Lovett Medidata 👇🏼

Preclinical studies validate the potential of #ApTOLL developed by aptaTargets to reduce inflammation and regenerate myelin in models of #MultipleSclerosis. Results published in British Journal of Pharmacology (BJP): bit.ly/3WPkbF4

A new study shows the cerebroprotective effects of #ApTOLL on mice with #AcuteIschemicStroke: bit.ly/3yR1ZAX The study, published in "Pharmaceutics" (Pharmaceutics MDPI), was conducted by researchers at aptaTargets (Dr. Macarena Hernández) and IIS La Fe (Dr. Juan Salom).

⚕️Today on #WorldHealthDay, we're highlighting three top #eicBAS beneficiaries driving better #HealthForAll and #HopefulFutures globally: 💡 SymPhysis Medical 🧠 aptaTargets 🩺 Better Medicine Check them out 👉 tinyurl.com/yntdfexc

.aptaTargets transfiere ApTOLL a Merck biotech-spain.com/es/articles/ap…

#Industria | aptaTargets transfiere ApTOLL a Merck 📰 tinyurl.com/yv9dsuap aptaTargets Merck España

.aptaTargets has announced an agreement with German pharmaceutical giant Merck for the clinical development and commercialisation of ApTOLL, a TLR4 antagonist being developed to treat acute ischaemic #Stroke neuronewsinternational.com/merck-assumes-…

.Inveready has achieved a 4x return on its Innvierte Biotech II fund. Benchmark Spanish financial newspaper expansioncom highlights aptaTargets among its top investments. aptaTargets recently transferred its drug #ApTOLL to Merck.

#Investigación | ➡️El emprendimiento en el ámbito biomédico va acompañado de algunas metas a superar específicas de este sector. ➡David Segarra, CEO de aptaTargets, cuenta los obstáculos a superar en el escalado de la innovación en este sector. diariomedico.com/medicina/inves…

#Investigación | ➡️El emprendimiento en el ámbito biomédico va acompañado de algunas metas a superar específicas de este sector. ➡David Segarra, CEO de aptaTargets, cuenta los obstáculos a superar en el escalado de la innovación en este sector. diariomedico.com/medicina/inves…

#ApTOLL’s secondary analysis data of APRIL 1b/2a trial published in scientific journal “Stroke” from American Heart Association: aptatargets.com/newsroom/aptol… #stroke #AcuteIschemicStroke #cerebroprotection